Novel mesenchymal progenitor cells derived from human blastocyst-derived stem cells
OwnerRaimund Strehl, Katarina Emanuelsson +2inventors
InventorsRaimund Strehl, Katarina Emanuelsson, Fredrik Wessberg, Sven Johan Hyllner
Life of this patent
Estimating the term…
Abstract
Described herein is a mesenchymal human progenitor (hBS-MP) cell population derived from human blastocyst-derived stem (hBS) cells and a method to obtain the progenitor cell population in which is eliminated the need of co-culture steps, cell sorting, manual selection, and transfections. Also, the use of the hBS-MP cells in drug discovery and specifically for toxicity testings as well as for therapeutic use is made possible.
Claims60
A novel mesenchymal human progenitor (hBS-MP) cell population negative for Sialic acid Neu5Gc and derived under xeno-free conditions from human blastocyst-derived stem (hBS) cells, wherein:
- i) at least 80% of said cell population is negative for at least two markers reacting with undifferentiated hBS cells;
- ii) at least 80% of said cell population is negative for at least one marker reacting with ectodermal lineage;
- iii) at least 80% of said cell population is negative for at least one marker reacting with endodermal lineage;
- and
- iv) at least 30% of said cell population is positive for at least one marker reacting with mesodermal lineage and the marker being selected from vimentin and desmin.
(canceled)
(canceled)
A method to obtain an hBS-derived stem cell derived mesenchymal progenitor (hBS-MP) cell population without manual selection, said method comprising;
- i) plating of undifferentiated hBS cells onto the surface;
- ii) incubation of the plated cells for between 2 and 21 days to allow differentiation;
- iii) enzymatic passaging to a second surface;
- iv) repeating of step (iii) until a homogenously mesenchymal morphology is obtained;
- and
- v) optionally, culturing the obtained hBS-MP cells.
(canceled)
(canceled)
Dependencies are inferred from the claim text.